Devendra Hiwase
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.
Qualifications: MBBS, MD, FRACP, FRCPA, PhD
Practice Responsibilities: Clinical and laboratory haematology
Specialities: Malignant haematology and stem cell transplantation
Site: Royal Adelaide Hospital (RAH), Haematology Department
A/Prof Devendra Hiwase is a Consultant Haematologist at the Royal Adelaide Hospital, Senior Lecturer, University of Adelaide and Senior Research Fellow at South Australia Health Medical Research Institute (SAHMRI). He has a special interest in myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and stem cell transplantation. In 2012, he started the MDS Research Group and South Australian MDS (SA-MDS) registry. Currently, the Group is involved in clinical and translational research projects, including mutational profiling, identifying novel biomarkers, and exploring the impact of nursing case management and comprehensive geriatric assessment on patients with MDS and related disorders.
A/Prof Hiwase’s research focuses on the pathogenesis of myeloid neoplasms and has presented his research findings in multiple international and national meetings and published in peer reviewed journals.
He serves on the editorial board of Leukemia Research and as a reviewer for speciality journals such as Haematologica, Leukemia and Lymphoma, as well as British Journal of Haematology. He is also a subject expert reviewer (external) for NHMRC project grants and has made regular contributions to teaching, provision of specialist medical services, and involvement in local and national committees. Dr Hiwase is a fellow of RACP, RCPA and member of the Australasian Leukaemia and Lymphoma Group (ALLG), Haematology Society of Australasia and New Zealand (HSANZ), American Society of Hematology, and a steering committee member of the national MDS and Aplastic Anaemia registry.
Myeloid neoplasms including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are a group of blood cancers that frequently affect older people. Some patients develop MDS/AML after treatment for their primary cancer (i.e. prostate cancer, breast cancer). This group of patients are known as having therapy-related myeloid neoplasms (T-MN). There are very limited treatment options for T-MN and the survival of these patients is poor. The MDS/AML Research Group focuses on improving the clinical outcome of patients by optimising current therapies and developing new therapies.
Our research group is split into two main arms of MDS/AML research – clinical research and basic science research. The clinical team focuses on patients’ health-related issues including developing global assessment tools to assess patients’ psycho-social needs, quality of life, overall health issues, and treatment-related toxicity. We also aim to improve treatment strategies by studying other factors, such as the management of infections, transfusion support, geriatric support, anticoagulation bleeding support and autoimmune diseases. The basic science team focuses on understanding the molecular pathogenesis of MDS/AML and identify biomarkers (i.e. predisposing mutations, abnormal bone marrow environment caused by long-term chemotherapy and drug resistance proteins) which can potentially change management and developing novel therapeutic approaches.
-
Appointments
Date Position Institution name 2021 - ongoing Clinical Associate Professor The University of Adelaide -
Language Competencies
Language Competency English Can read, write, speak, understand spoken and peer review -
Research Interests
-
Journals
Year Citation 2022 Beckmann, K., Kearney, B. J., Yeung, D., Hiwase, D., Li, M., & Roder, D. M. (2022). Changes in five-year survival for people with acute leukaemia in South Australia, 1980-2016. Medical Journal of Australia, 216(6), 296-302.
Scopus1 WoS12022 Shah, M. V., Chhetri, R., Dholakia, R., Kok, C. H., Gangat, N., Alkhateeb, H. B., . . . Hiwase, D. (2022). Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. American Journal of Hematology, 97(8), 1013-1022.
2021 Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256.
Scopus12 WoS11 Europe PMC32021 Ravandi, F., Roboz, G. J., Wei, A. H., Döhner, H., Pocock, C., Selleslag, D., . . . Dombret, H. (2021). Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Journal of Hematology and Oncology, 14(1), 14 pages.
Scopus1 WoS12021 Samaraweera, S. E., Wang, P. P. S., Li, K. L., Casolari, D. A., Feng, J., Pinese, M., . . . D'Andrea, R. J. (2021). Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood, 138(22), 2293-2298.
2021 Tiong, I. S., Dillon, R., Ivey, A., Kuzich, J. A., Thiagarajah, N., Sharplin, K. M., . . . Wei, A. H. (2021). Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 5(23), 5107-5111.
Scopus2 WoS2 Europe PMC12021 Sharplin, K., Wee, L. Y. A., Singhal, D., Edwards, S., Danner, S., Lewis, I., . . . Hiwase, D. K. (2021). Outcomes and health care utilization of older patients with acute myeloid leukemia.. Journal of geriatric oncology, 12(2), 243-249.
Scopus3 WoS1 Europe PMC12021 Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207.
Scopus25 WoS22 Europe PMC102020 Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Friel, O., Pham, A., Salvi, A., . . . Hiwase, D. K. (2020). The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. Transfusion, 60(10), 2192-2198.
Scopus3 WoS2 Europe PMC12020 Brown, A. L., & Hiwase, D. K. (2020). What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening. Leukemia Research, 96, 3 pages.
Scopus2 WoS22020 Marinelli, T., Wee, L. Y. A., Rowe, E., Chhetri, R., Friel, O., Higgins, G., . . . Hiwase, D. K. (2020). Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 26(4), 782-788.
Scopus9 WoS8 Europe PMC42020 Kuzmanovic, T., Patel, B. J., Sanikommu, S. R., Nagata, Y., Awada, H., Kerr, C. M., . . . Radivoyevitch, T. (2020). Genomics of therapy-related myeloid neoplasms. Haematologica, 105(3), E98-E101.
Scopus13 WoS13 Europe PMC92020 Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C. -E., . . . Scott, H. S. (2020). RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 4(6), 1131-1144.
Scopus44 WoS45 Europe PMC212020 Molga, A., Wall, M., Chhetri, R., Wee, L. Y., Singhal, D., Edwards, S., . . . Hiwase, D. (2020). Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. Journal of Geriatric Oncology, 11(1), 114-120.
Scopus23 WoS22 Europe PMC92020 Molga, A., Wall, M., Wee, L. Y. A., Chhetri, R., Singhal, D., Singhal, N., . . . Hiwase, D. (2020). Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes.. Journal of geriatric oncology, 11(1), 128-130.
Scopus2 WoS2 Europe PMC12020 Roberts, M. B., Bak, N., Wee, L. Y. A., Chhetri, R., Yeung, D. T., Lewis, I., & Hiwase, D. K. (2020). Clinical Effectiveness of Conjugate Pneumococcal Vaccination In Hematopoietic Stem Cell Transplant Recipients.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(2), 421-427.
Scopus6 WoS7 Europe PMC12020 Brown, A. L., Hahn, C., Hiwase, D., Godley, L. A., & Scott, H. S. (2020). Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. LEUKEMIA & LYMPHOMA, 61(1), 2 pages.
Scopus2 WoS2 Europe PMC12019 Ho, P. J., Hiwase, D., Ramakrishna, R., Viiala, N., Solterbeck, A., Traficante, R., . . . Bowden, D. K. (2019). Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: The TIMES study. HemaSphere, 3(3), 11 pages.
Scopus5 WoS5 Europe PMC22019 Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., . . . Hiwase, D. K. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 33(12), 2842-2853.
Scopus22 WoS21 Europe PMC112019 Shanmuganathan, N., Braley, J., Yong, A., Hiwase, D., Yeung, D., Ross, D., . . . Branford, S. (2019). Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood, 134(1), 85-89.
Scopus16 WoS16 Europe PMC72019 Germing, U., Oliva, E. N., Hiwase, D., & Almeida, A. (2019). Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HemaSphere, 3(6), 9 pages.
Scopus13 WoS13 Europe PMC72019 Kenealy, M., Hertzberg, M., Benson, W., Taylor, K., Cunningham, I., Stevenson, W., . . . Seymour, J. F. (2019). Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. HAEMATOLOGICA, 104(4), 700-709.
Scopus7 WoS7 Europe PMC12019 Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances, 3(3), 370-374.
Scopus2 WoS22019 Clucas, D. B., Fox, L. C., Wood, E. M., Hong, F. S., Gibson, J., Bajel, A., . . . Wood, E. (2019). Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. INTERNAL MEDICINE JOURNAL, 49(2), 152-159.
Scopus5 WoS5 Europe PMC42019 Chhetri, R., Wee, L. Y. A., Sinha, R., Kutyna, M. M., Pham, A., Stathopoulos, H., . . . Hiwase, D. K. (2019). Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: Prevalence, characteristic and significance. Haematologica, 104(10), E451-E454.
Scopus9 WoS9 Europe PMC22018 New-Tolley, J., Smith, C., Koszyca, B., Otto, S., Maundrell, A., Bardy, P., . . . Limaye, V. (2018). Inflammatory myopathies after allogeneic stem cell transplantation. Muscle and Nerve, 58(6), 790-795.
Scopus10 WoS11 Europe PMC12018 Hiwase, D., & Ross, D. (2018). Success is built on failures: tackling the challenge of ponatinib failure. Leukemia and Lymphoma, 59(6), 1279-1281.
Scopus1 WoS12018 Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . . Hughes, T. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leukemia Research, 67, 109-115.
Scopus7 WoS7 Europe PMC32018 Schwarer, A. P., Butler, J., Jackson, K., Beligaswatte, A., Martin, L., Kennedy, G., . . . Marlton, P. (2018). A Comparison of High-Dose Cytarabine during Induction Versus Consolidation Therapy in Newly Diagnosed AML. HemaSphere, 2(6), e158.
Scopus22017 Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 102(12), 2021-2029.
Scopus31 WoS27 Europe PMC142017 Hiwase, D., Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., . . . Germing, U. (2017). Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. American Journal of Hematology, 92(6), 508-514.
Scopus20 WoS19 Europe PMC82017 Hiwase, D. (2017). The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. Leukemia Research, 57, 102-103.
2017 Shanmuganathan, N., Hiwase, D., & Ross, D. (2017). Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leukemia and Lymphoma, 58(12), 2799-2810.
Scopus14 WoS16 Europe PMC42017 Cheah, J., Hahn, C., Hiwase, D., Scott, H., & Brown, A. (2017). Myeloid neoplasms with germline DDX41 mutation. International Journal of Hematology, 106(2), 163-174.
Scopus45 WoS43 Europe PMC282016 Dawar, S., Shahrin, N., Sladojevic, N., D'Andrea, R., Dorstyn, L., Hiwase, D., & Kumar, S. (2016). Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice. Cell Death and Disease, 7(12), e2509-1-e2509-9.
Scopus18 WoS19 Europe PMC132016 Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . . . White, D. (2016). TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 30(6), 1263-1272.
Scopus31 WoS27 Europe PMC182015 Hahn, C., Ross, D., Feng, J., Beligaswatte, A., Hiwase, D., Parker, W., . . . Scott, H. (2015). A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia, 29(10), 2101-2104.
Scopus23 WoS22 Europe PMC202015 Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923.
Scopus68 WoS59 Europe PMC362015 Hahn, C., Venugopal, P., Scott, H., & Hiwase, D. (2015). Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunological Reviews, 263(1), 257-278.
Scopus31 WoS27 Europe PMC252015 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85.
Scopus27 WoS27 Europe PMC222014 Nievergall, E., Ramshaw, H., Yong, A., Biondo, M., Busfield, S., Vairo, G., . . . Hiwase, D. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123(8), 1218-1228.
Scopus69 WoS67 Europe PMC522014 Hiwase, D. K., Hahn, C. N., Babic, M., Moore, S., Butcher, C. M., Kutyna, M. M., . . . Scott, H. S. (2014). Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes. BLOOD, 124(21), 3 pages. 2013 Puccini, J., Shalini, S., Voss, A., Gatei, M., Wilson, C., Hiwase, D., . . . Kumar, S. (2013). Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 110(49), 19920-19925.
Scopus51 WoS51 Europe PMC392013 Hiwase, D., Saunders, V., Nievergall, E., Ross, D., White, D., & Hughes, T. (2013). Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Haematologica, 98(6), 896-900.
Scopus8 WoS9 Europe PMC72013 White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204.
Scopus7 WoS7 Europe PMC62013 Chow, A., Lee, C., Hiwase, D., To, L., & Horvath, N. (2013). Relapsed multiple myeloma: who benefits from salvage autografts?. Internal Medicine Journal, 43(2), 156-161.
Scopus13 WoS10 Europe PMC82013 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705.
WoS12012 Hiwase, D., & Hughes, T. (2012). Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 53(7), 1251-1252.
Scopus3 WoS1 Europe PMC12011 To, L., Levesque, J., Herbert, K., Winkler, I., Bendall, L., Hiwase, D., . . . Lewis, I. (2011). Mobilisation strategies for normal and malignant cells. Pathology, 43(6), 547-565.
Scopus9 WoS7 Europe PMC52011 Hiwase, D., Yeung, D., & White, D. (2011). Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Review of Hematology, 4(3), 285-299.
Scopus6 WoS6 Europe PMC42011 Foot, N., Leong, Y., Dorstyn, L., Dalton, H., Ho, K., Zhao, L., . . . Kumar, S. (2011). Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis. Blood, 117(2), 638-646.
Scopus31 WoS31 Europe PMC272010 Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778.
Scopus47 WoS40 Europe PMC312010 Hiwase, D., White, D., Zrim, S., Saunders, V., Vaz de Melo, J., & Hughes, T. (2010). Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 24(3), 658-660.
Scopus25 WoS25 Europe PMC212009 Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL<sup>+</sup> cells. Leukemia, 23(6), 1205-1206.
Scopus16 WoS15 Europe PMC112008 Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888.
Scopus156 WoS142 Europe PMC1152008 Hiwase, D., Hiwase, S., Bailey, M., Bollard, G., & Schwarer, A. (2008). The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy, 10(5), 507-517.
Scopus16 WoS13 Europe PMC112008 Hiwase, D., Hiwase, S., Bailey, M., Bollard, G., & Schwarer, A. (2008). Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 14(1), 116-124.
Scopus69 WoS63 Europe PMC502007 Hiwase, D. K., Bollard, G., Hiwase, S., Bailey, M., Muirhead, J., & Schwarer, A. P. (2007). Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy, 9(6), 539-547.
Scopus44 WoS42 Europe PMC322002 Mohite, U., Pathare, A., Al Kindi, S., Hiwase, D., Vadakkepat, N., & Knox-Macaulay, H. (2002). Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia. Haematologia, 32(4), 495-499. 2002 Knox-Macaulay, H. H. M., Hiwase, D., Nusrat, N., & Ganesh, A. (2002). Pseudotumour cerebri occurring before treatment of acute promyelocytic leukaemia with all-trans-retinoic acid (ATRA). Haematologia, 32(1), 81-85.
Scopus1 Europe PMC12000 Ghosh, K., Mitra, S., & Hiwase, D. (2000). Choroidal infiltrates simulating fundal changes of acute leukemia during hematological recovery following high-dose chemotherapy in acute myelomonocytic leukemia in remission. American Journal of Hematology, 63(1), 42-45.
Scopus3 Europe PMC22000 Ghosh, K., Daar, S., Hiwase, D., & Nusrat, N. (2000). Primary Pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient. Haematologia, 30(1), 69-72.
Scopus11 Europe PMC52000 Ghosh, K., Hiwase, D., & Muirhead, D. (2000). Intense eosinophilia with abnormal ultrastructure as presenting manifestation of acute lymphoblastic leukemia. Haematologia, 30(2), 137-141.
2000 Ghosh, K., Khanduri, U., Hiwase, D., Venugopal, S., & Muirhead, D. (2000). Acute Myelomonocytic Leukaemia with Pseudo-Chediak-Higashi inclusions in leukaemic blasts report of an unusual case. Haematologia, 30(3), 229-234.
Scopus12000 Kulkarni, K., Parikh, P., Hiwase, D., Pai, V., Gopal, R., Saikia, T., & Advani, S. (2000). Letter to editor (multiple letters). Indian Journal of Hematology and Blood Transfusion, 18(1), 22-23. 1999 Ghosh, K., Muirhead, D., Christie, B., & Hiwase, D. (1999). Ultrastructural changes in peripheral blood neutrophils in a patient receiving ganciclovir for CMV pneumonitis following allogenic bone marrow transplantation. Bone Marrow Transplantation, 24(4), 429-431.
Scopus2 Europe PMC2 -
Book Chapters
Year Citation 2011 Hiwase, D. K., & Hughes, T. P. (2011). Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. In Leukemias: Principles and Practice of Therapy (pp. 281-295). Wiley.
2008 Hiwase, D., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117). -
Conference Papers
Year Citation 2020 Ravandi, F., Pocock, C., Selleslag, D., Montesinos, P., Sayar, H., Musso, M., . . . Dombret, H. (2020). Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S187-S188). CIG MEDIA GROUP, LP.
WoS12019 Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Salvi, A., Mcrae, S., Roxby, D. J., . . . Hiwase, D. K. (2019). The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2019 Sharplin, K., Wee, L. Y. A., Edwards, S., Danner, S., Yong, A. S., Singhal, D., & Hiwase, D. (2019). Outcomes and Healthcare Utilization in Older Patients with Acute Myeloid Leukemia (AML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S224). CIG MEDIA GROUP, LP.
2019 Singhal, D., Hahn, C. N., Moma, L. D., Wee, L. Y. A., Chhetri, R., Babic, M., . . . Hiwase, D. K. (2019). Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12019 Brown, A. L., Babic, M., Schreiber, A., Feng, J., Dobbins, J., Arts, P., . . . Scott, H. S. (2019). Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12019 Hahn, C. N., Babic, M., Brautigan, P. J., Venugopal, P., Phillips, K., Dobbins, J., . . . Scott, H. S. (2019). Australian Familial Haematological Cancer Study - Findings from 15 Years of Aggregated Clinical, Genomic and Transcriptomic Data. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12019 Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Giri, P., . . . Hiwase, D. K. (2019). An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2019 Unnikrishnan, A., Lim, X. Y., Joshi, S., Nunez, A. C., Vaughan, L., Pickford, R., . . . Pimanda, J. (2019). In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2018 Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP.
2017 Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Al-Kali, A., Hiwase, D., Baer, M. R., Greenberg, P., Shortt, J., Collins, R., . . . Silverman, L. R. (2017). Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA). In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12017 Singhal, D., Wee, A., Parker, W., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2017). Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS12017 Hahn, C. N., Wee, A., Babic, M., Feng, J., Wang, P., Kutyna, M. M., . . . Scott, H. S. (2017). Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS12016 Schwarer, A. P., Wight, J., Jackson, K., Beligaswatte, A. M., Butler, J. P., Kennedy, G., . . . Marlton, P. (2016). High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?. In BLOOD Vol. 128 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY.
WoS212016 Brown, A. L., Hahn, C. N., Carmichael, C., Wilkins, E., Babic, M., Chong, C. -E., . . . Scott, H. S. (2016). Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Garcia-Manero, G., Fenaux, P., Al-Kali, A., Navada, S. C., Baer, M. R., Raza, A., . . . Silverman, L. R. (2016). Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
WoS102016 Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., Nath, S., . . . Germing, U. (2016). RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients: analysis of South Australian and Dusseldorf MDS registries. In Proceedings of the 58th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood Vol. 128 (pp. 1998). San Diego, CA: American Society of Hematology. 2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Nath, S. V., . . . Germing, U. (2016). RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. 2016 Singhal, D., Wee, L. A., Parker, W. T., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2016). The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2015 Singhal, D., Hague, S., Roxby, D., Wee, L. A., Lee, O. -L., Sinha, R., . . . Hiwase, D. K. (2015). RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hahn, C. N., Babic, M., Schreiber, A. W., Kutyna, M. M., Wee, L. A., Brown, A. L., . . . Hiwase, D. (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS22015 Hoi, P. J., Hiwase, D., Ramakrishna, A., Viiala, N., Ross, D. M., Zor, E., & Gervasio, O. L. (2015). Prevalence of Cardiac and H sis in Australian Patients with Transfusion-Dependent Anemias or No -Dependent Thalassemia, As Assessed By MRI (the TIMES study). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hiwase, D., Hahn, C., Babic, M., Moore, S., Singhal, D., Kutyna, M., . . . Scott, H. (2015). MULTIPLE MUTATIONS IN THE SAME GENE SUGGEST CLONAL DIVERSITY AND IS ASSOCIATED WITH POOR PROGNOSIS IN MDS. In LEUKEMIA RESEARCH Vol. 39 (pp. S77-S78). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
2015 Hiwase, D., Moore, S., Kutyna, M., Fraser, R., Singhal, D., Chhetri, R., . . . Scott, H. (2015). SNP-MICROARRAY OF PERIPHERAL BLOOD-GRANULOCYTES DNA CAN DETECT CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS). In LEUKEMIA RESEARCH Vol. 39 (pp. S79-S80). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
2015 Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2015). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. In LEUKEMIA RESEARCH Vol. 39 (pp. S5). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
WoS32015 Hiwase, D., Moore, S., Hahn, C., Kutyna, M., Van der Hoek, M., Fraser, R., . . . Scott, H. (2015). TARGETED MUTATION SEQUENCING AND SNP-MICRORRAY CAN IDENTIFY POOR PROGNOSTIC GROUP IN IPSS-LOWER RISK GROUP. In LEUKEMIA RESEARCH Vol. 39 (pp. S78-S79). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD.
2013 Hiwase, D. K., Kutyna, M. M., Chhetri, R., Howell, S., Harrison, P. B., Nath, S. V., . . . To, L. B. (2013). Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS22011 Chow, A. W., Lee, C. H., Hiwase, D. K., To, L. B., & Horvath, N. (2011). Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?. In BLOOD Vol. 118 (pp. 1319). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-alpha Increases the Susceptibility of CD34(+) CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12010 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY.
WoS102010 Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. 2010 Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34(+) Progenitors Is Not Significantly Different Than That Observed In CD34(-) Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology.
2009 Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY. 2008 Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY. 2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS72007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology.
-
Conference Items
Year Citation 2019 Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Kutyna, M., Wechalekar, M., . . . Proudman, S. (2019). MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATOLOGICAL DISORDERS. Poster session presented at the meeting of ANNALS OF THE RHEUMATIC DISEASES. Madrid, SPAIN: BMJ PUBLISHING GROUP.
2019 Kutyna, M. M., Wee, A., Paton, S., Cakouros, D., Arthur, A., Chhetri, R., . . . Hiwase, D. K. (2019). Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN). Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
WoS22018 Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS52018 Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Singhal, N., . . . Hiwase, D. K. (2018). Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS12018 Singhal, D., Wee, A., Kutyna, M. M., Babic, M., Chhetri, R., Parker, W., . . . Hiwase, D. K. (2018). Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
2018 Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Wechalekar, M. D., Proudman, S., & Hiwase, D. K. (2018). The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
2018 Pradhan, A., Chhetri, R., Wee, A., Malhotra, R., Singhal, D., Nelson, R., . . . Hiwase, D. K. (2018). Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
2018 Chhetri, R., Wee, A., Sinha, R., Kutyna, M. M., Gupta, S., Nath, L., . . . Hiwase, D. K. (2018). Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS12017 Singhal, D., Wee, L. A., Babic, M., Parker, W., Moore, S., Feng, J., . . . Hiwase, D. (2017). THERAPY RELATED MYELOID NEOPLASMS (T-MN) SHOW HIGH MUTATION FREQUENCY AND A SPECTRUM DIFFERENT FROM PRIMARY MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
2017 Singhal, D., Chhetri, R., Wee, L. A., Kutyna, M., Nath, S., & Hiwase, D. (2017). IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED SURVIVAL IN LOWER RISK MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
2016 Singhal, D., Moore, S., Kutyna, M., Chhetri, R., Wee, L. A., Gray, J., . . . Hiwase, D. (2016). THERAPY RELATED MYELOID NEOPLASM FOLLOWING RADIOTHERAPY HAS HIGHER INCIDENCE OF POOR RISK CYTOGENETICS AND ARE ASSOCIATED WITH POOR SURVIVAL COMPARED TO DE NOVO MDS CASES. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Ho, P., Hiwase, D., Ramakrishna, R., Viiala, N., Ross, D., Zor, E., . . . Bowden, D. (2016). THE IMPACT OF CARDIAC AND HEPATIC MRI ASSESSMENT ON THE CLINICAL MANAGEMENT OF AUSTRALIAN PATIENTS WITH TRANSFUSION DEPENDENT ANEMIAS OR NON-TRANSFUSION-DEPENDENT THALASSEMIA IN THE TIMES STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2014 Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2014). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE IN HIGHER RISK MDS IS DELIVERABLE WITH HIGHER RESPONSE RATES; FIRST ANALYSIS OF THE ALLG MDS4 RANDOMISED PHASE II STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
WoS12014 Hiwase, D. K., Singhal, D., Chhetri, R., Kutyna, M. M., Harrison, P. B., Nath, S. V., . . . To, L. B. (2014). Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. 2013 Hiwase, D., Kutyna, M., Carr, T., Harrison, P., Melo, J. V., Bardy, P., & To, L. B. (2013). Transfusion dependency is associated with inferior outcome in very low- and low-risk IPSS-R patients. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
2013 Kenealy, M., Seymour, J. F., Benson, W., Stevenson, W., Eek, R., Zantomio, D., . . . Zannino, D. (2013). The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD.
WoS12013 Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS72013 White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. 2012 Amin, T., Elias, T., Hiwase, D., & Otto, S. (2012). SYSTEMIC MASTOCYTOSIS IS ASSOCIATED WITH MINIMAL CHANGE DISEASE. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL. 2012 Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of alpha-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
2012 Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
WoS32012 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
WoS8
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS and therapy-related myeloid neoplasms. Miller Bequest HSCGB (2020). $30,800. Devendra Hiwase.
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS and therapy-related myeloid neoplasms. Sail for Cancer HSCGB (2020). $30,000. Devendra Hiwase.
- Precision Medicine for Chronic Myelomonocytic Leukaemia: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort. MRFF Rare Cancers, Rare Diseases and Unmet Need APP1201012 (2019). $1,619,122. Timothy Hughes, Devendra Hiwase, David Ross, Daniel Thomas, David Yeung, Steven Lane, Agnes Yong, Angel Lopez, Timothy Hercus, John Reynolds.
- Understanding molecular pathogenesis of therapy related myeloid neoplasm. MRFF Investigator Grants MRF1195517 (2019). $560,105. Devendra Hiwase
- South Australian MDS-Database. Grant Funding, Novartis Pharmaceuticals Australia Pty Limited (2018). $60,000. Devendra Hiwase
- To evaluate the frequency of clonal haematopoiesis and risk of therapy-related myeloid neoplasm in primary cancer patients treated with chemo/radiotherapy. RAH Research Committee Clinical Project Grant (2018). $50,000. Nimit Singhal, Deepak Singhal, Devendra Hiwase, Chris Hahn, Hamish Scott
- Molecular pathogenesis of bone marrow failure and drug resistance in MDS. Miller Bequest HSCGB (2018). $75,886.50. Devendra Hiwase.
- Determine the clinical impact of mutation profile in ICUS, MDS and t-MN. Sail for Cancer HSCGB (2018). $38,220.67. Devendra Hiwase.
- Molecular profiling to improve diagnosis and develop therapeutic strategy for MDS/MPN overlap syndrome. Miller Bequest HSCGB (2017). $73,718. Ian Lewis, Devendra Hiwase, Amilia Wee
- Molecular Profiling of Idiopathic Cytopenia Undetermined Significance to Improve Diagnosis and Develop Prognostic Model. Sail for Cancer HSCGB (2017). $54,345. Ian Lewis, Devendra Hiwase, Amilia Wee
I lead the MDS/AML research group in the South Australian Health and Medical Institute (SAHMRI) and supervise a research assistant, data manager, senior nurse, two PhD students, advanced trainee registrars and medical students. I am actively involved teaching medical students and was awarded “Best teacher of the year” by the University of Adelaide.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 Co-Supervisor Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia Doctor of Philosophy Doctorate Full Time Miss Maha Mahmoud Ibrahim Mohamed Kamel 2021 Co-Supervisor Deciphering the Role of New Adaptors in Regulation of Nedd4 Ubiquitin Ligases Doctor of Philosophy Doctorate Full Time Mr Ryan Daniel Norton 2019 Co-Supervisor Frailty in Patients with Haematological Malignancies Doctor of Philosophy Doctorate Full Time Dr Angela Teresa Molga 2018 Co-Supervisor Evaluating Role of Bone Marrow Microenvironment and Cytokine signaling in Pathogenesis of Myelodysplastic Syndrome and Therapy-Related Myeloid Neoplasm Doctor of Philosophy Doctorate Full Time Mrs Monika Maria Kutyna
Connect With Me
External Profiles
